Karl Whitney

General Counsel at PASSAGE BIO, INC.

Health Technology

Consumer Services

Commercial Services

Profile

Karl Whitney is Senior Vice President-Global Regulatory Affairs at Passage Bio, Inc. since 2024.
Dr. Whitney is Co-President at International Foxp1 Foundation since 2021.
Formerly, Dr. Whitney was Vice President & Head-Regulatory Affairs at Precision BioSciences, Inc. from 2020 to 2024.
Dr. Whitney was Principal at Rho, Inc. Education includes undergraduate studies at Yale University and a doctorate from Duke University.

Karl Whitney active positions

Companies	Position	Start
PASSAGE BIO, INC.	General Counsel	31/01/2024

All active positions of Karl Whitney

Former positions of Karl Whitney

Companies	Position	End
PRECISION BIOSCIENCES, INC.	General Counsel	31/12/2023
Rho, Inc. Rho, Inc. Miscellaneous Commercial ServicesCommercial Services Provides collection processing and management of clinical research	Corporate Officer/Principal	-

See the detail of Karl Whitney's experience

Training of Karl Whitney

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Karl Whitney's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
Precision BioSciences, Inc. Precision BioSciences, Inc. BiotechnologyHealth Technology Develops technology to produce custom, genome-editing enzymes for human health and biological research	Health Technology
Duke University Duke University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Yale University Yale University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Rho, Inc. Rho, Inc. Miscellaneous Commercial ServicesCommercial Services Provides collection processing and management of clinical research	Commercial Services
Passage Bio, Inc. Passage Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of monogenic central nervous system disorders	Health Technology